HPK1-IN-62
HPK1-IN-62 is a selective and orally active HPK-1 inhibitor with an IC50 of 1.22 nM. HPK1-IN-62 significantly improves GLK selectivity (> 665-fold) and LCK selectivity (> 1095-fold) . HPK1-IN-62 enhances T-cell activation and demonstrated synergistic effects when combined with anti-mPD-1 therapy in the MC38 tumor model, inhibiting a tumor growth. HPK1-IN-62 can be used in the researchs of colon cancer and cancer immunotherapy[1].
Product Specifications
UNSPSC
12352005
Target
MAP4K
Related Pathways
MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
N#CC1=C2C=C(NC3=NC(N[C@@H](C4=C(OCCCC2)C=CC=C4)CO)=C(C=N3)C5=CC(N6CC[C@H](C6)O)=NC=C5)C=C1
Molecular Formula
C32H33N7O3
Molecular Weight
563.65
References & Citations
[1]Duan CX, et al. Design, synthesis, and biological evaluation of 2-substituted-pyridin-4-yl macrocyclic derivatives as new selective HPK1 inhibitors. Bioorg Chem. 2025 Aug 27;165:108925.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MAP4K1/HPK1; MAP4K2/GCK; MAP4K3/GLK
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
A02709-5-FITC 100 µg/Vial
Anti-NKX3-1 Antibody Picoband® FITC Conjugated
Sign In for Pricing
View Details 51049114 3x 1.0 µg
Zfp61 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
Sign In for Pricing
View Details